Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X:
“Hot off the press!
Pleased to share our new paper, led by the amazing Juliana Beal, Niamh Coleman, Jia (Jenny) Liu.
- Precision before incision: neoadjuvant tumor-agnostic therapies.
- Nine tumor-agnostic drugs now have a case for earlier use, before resistance sets in and with organ preservation in mind.
- A PD-1 blockade hit a 100% complete response in MMR-deficient rectal cancer.”
Title: Precision before incision: neoadjuvant tumor-agnostic therapies
Authors: Juliana Beal, Niamh Coleman, Jia Liu, Jason K. Sicklick, Julian Bryan, Vivek Subbiah
You can also read:
Vivek Subbiah Showcases Real-Time Precision Oncology at the WIN Symposium
